Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis
- 15 June 2005
- journal article
- clinical trial
- Published by Wiley in Journal of Surgical Oncology
- Vol. 90 (4) , 220-225
Abstract
Background Peritoneal carcinomatosis (PC) is a major disease, currently treated using complete cytoreductive surgery and intraperitoneal chemohyperthermia (IPCH). Morbidity is a significant limitation of this procedure, usually related to the extent of surgery, and hematological toxicity, which is considered as dependent upon the chemotherapy dosage alone. The aim of our study was to investigate whether surgery alone had an impact on the hematological toxicity associated with the standardized drug protocol that we routinely prescribed. Methods Data were prospectively recorded from 83 consecutive patients who underwent complete cytoreductive surgery followed by IPCH with intraperitoneal oxaliplatin (360 mg/m2) and irinotecan (360 mg/m2), in 2 L/m2 of dextrose over 30 min at 42–45°C, using the Coliseum technique. Sixty minutes prior to IPCH, patients also received an intravenous perfusion of leucovorin (20 mg/m2) and 5‐fluorouravyl (400 mg/m2). The doses and volume of IPCH were determined on the basis of the body surface area, so that all patients received the same concentration of drugs. Severe aplasia were defined as a leucocyte count of P = 0.002), and to the extent of the peritoneal disease (peritoneal index of 19.5 in the aplastic group, vs. 15.3 in the nonaplastic group) (P = 0.02). Conclusion We report for the first time that the duration of surgery may increase the incidence of hematological toxicity following intraperitoneal chemotherapy. We also hypothesized that intra‐ and postoperative transient biochemical disorders, such as hypoalbuminemia, hemodilution, liver, and renal insufficiency and stress can be involved in this process. These hypotheses may allow improved postoperative care. J. Surg. Oncol. 2005;90:220–225.Keywords
This publication has 23 references indexed in Scilit:
- Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and toleranceAnnals of Oncology, 2004
- Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapyBritish Journal of Surgery, 2004
- Bone Marrow Failure Following Severe Injury in HumansAnnals of Surgery, 2003
- Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal CancerJournal of Clinical Oncology, 2003
- Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokineticsCancer Chemotherapy and Pharmacology, 2003
- Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distributionAnnals of Oncology, 2002
- Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancerBritish Journal of Surgery, 2000
- Peritonectomy ProceduresAnnals of Surgery, 1995
- Measurements of Peritoneal Surface Area in Man and RatThe American Journal of the Medical Sciences, 1988
- The Importance of the Abdominal Viscera to Peritoneal Transport During Peritoneal Dialysis in the DogThe American Journal of the Medical Sciences, 1986